Sugi Predict

Sugi Predict / Compounds / SCHEMBL316685

SCHEMBL316685

SCHEMBL316685

COC1CCN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 1/20 0.50
▸ PIK3CD O00329 2/20 0.48
▸ RECQL P46063 1/20 0.48
▸ EPHX1 P07099 1/20 0.48
▸ USP30 Q70CQ3 2/20 0.46
▸ PDE4B Q07343 1/20 0.46
▸ USP2 O75604 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ MAPT P10636 2/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ GPR119 Q8TDV5 1/20 0.44
▸ NR1H2 P55055 1/20 0.44
▸ PRMT5 O14744 1/20 0.44
▸ WDR77 Q9BQA1 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.43
▸ THRB P10828 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL316684 1.00 HPGD (0.50) HPGDPIK3CDRECQLEPHX1USP30
SCHEMBL84791 1.00 HPGD (0.50) HPGDPIK3CDRECQLEPHX1USP30
SCHEMBL1771389 0.90 MEN1 (0.53) HPGDPIK3CDRECQLEPHX1USP30
SCHEMBL791930 0.90 MEN1 (0.53) HPGDPIK3CDRECQLEPHX1USP30
SCHEMBL15696592 0.90 MEN1 (0.53) HPGDPIK3CDRECQLEPHX1USP30
SCHEMBL85477 0.89 HPGD (0.57) HPGDRECQLEPHX1PDE4BUSP2
SCHEMBL31208922 0.87 USP30 (0.47) HPGDPIK3CDRECQLEPHX1USP30
SCHEMBL12083457 0.86 HPGD (0.50) HPGDPIK3CDRECQLEPHX1USP30
SCHEMBL21780520 0.86 HPGD (0.50) HPGDPIK3CDRECQLEPHX1USP30
SCHEMBL4574297 0.86 HPGD (0.50) HPGDPIK3CDRECQLEPHX1USP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080200454-A1 CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S SUNESIS PHARMACEUTICALS, INC. 2008-08-21 — — US claimed
WO-2008100618-A2 CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S SUNESIS PHARMACEUTICALS, INC. (US) 2008-08-21 — — WO claimed
CN-114591212-B Human plasma kallikrein inhibitors 拜奥克里斯特制药公司 2025-01-28 — — CN disclosed
CN-119233976-A Modulators of c-MYC mRNA translation and their use in the treatment of cancer 艾尼莫生物科技公司 2024-12-31 — — CN disclosed
CN-118632841-A Heterocyclic compounds for the treatment of cancer 阿提奥斯医药有限公司 2024-09-10 — — CN disclosed
CN-115335369-B GEM-disubstituted piperidine melanocortin subtype-2 receptor (MC 2R) antagonists and uses thereof 克林提克斯医药股份有限公司 2024-07-02 — — CN disclosed
CN-112204028-B tetrahydro-1H-pyrazino [2,1-a ] isoindoloquinoline compounds for use in the treatment of autoimmune diseases 豪夫迈·罗氏有限公司 2023-12-29 — — CN disclosed
CN-117062818-A Novel SOS1 inhibitor and preparation method and application thereof 南京再明医药有限公司 2023-11-14 — — CN disclosed
US-11718638-B2 Compounds, compositions and methods for synthesis WAVE LIFE SCIENCES LTD. (SG) 2023-08-08 — — US disclosed
EP-4219478-A1 METHOD OF PREPARING AMINO PYRIMIDINE DERIVATIVES Novartis AG (CH) 2023-08-02 — — EP disclosed
WO-2023140369-A1 PHOSPHORIC ACID DERIVATIVES Prism BioLab Co., Ltd. (JP) 2023-07-27 — — WO disclosed
EP-1877404-A2 NOVEL CYCLIC AMINES F. Hoffmann-Roche AG (CH) 2008-01-16 — — EP disclosed
EP-1592426-B1 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF NOVARTIS AG (CH) 2007-12-19 — — EP disclosed
US-20070244090-A9 PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSPHORYLASE BRADLEY STUART E 2007-10-18 — — US disclosed
US-20060247251-A1 2-Cyanopyrrolopyrimidines and pharmaceutical uses thereof NOVARTIS AG (CH) 2006-11-02 — — US disclosed
WO-2006114401-A2 NOVEL CYCLIC AMINES F. HOFFMANN-LA ROCHE AG (CH) 2006-11-02 — — WO disclosed
US-20050261272-A1 Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase PROSIDION LIMITED (GB) 2005-11-24 — — US disclosed
EP-1592426-A1 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF Novartis AG (CH) 2005-11-09 — — EP disclosed
WO-2004069829-A1 (2S)-2-((PYRIMIDIN-4-YL)AMINO)-4-METHYLPENTANOIC ACID AMINOETHYLAMID DERIVATIVES AS IL-8 RECEPTOR MODULATORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND RHEUMATOID ARTHRITIS PHARMACOPEIA DRUG DISCOVERY, INC. (US) 2004-08-19 — — WO disclosed
WO-2004069256-A1 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF NOVARTIS AG (CH) 2004-08-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060247251-A1 2-Cyanopyrrolopyrimidines and pharmaceutical uses thereof DPYD, P2RY1, P2RY2 HPGD 340/4885PIK3CD 1729/4885RECQL 186/4885
US-11718638-B2 Compounds, compositions and methods for synthesis ALKBH1, DUT, RNGTT HPGD 3802/4885PIK3CD 1498/4885RECQL 535/4885
US-20080200454-A1 CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S CTSS, CTSK, CTSZ HPGD 1243/4885PIK3CD 2494/4885RECQL 4413/4885
US-20070244090-A9 PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSPHORYLASE PYGL, PYGM, PYGB HPGD 306/4885PIK3CD 325/4885RECQL 1614/4885
US-20050261272-A1 Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase PYGL, PYGM, PYGB HPGD 306/4885PIK3CD 325/4885RECQL 1614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.